DIAGNOS Announces the Engagement of IBN

DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a leader in utilizing Artificial Intelligence (AI) for early detection of critical eye-related health issues, has announced a strategic engagement with Investor Brand Network (IBN) to enhance its corporate communications and market awareness. Effective from January 10, 2026, this partnership is set for one year, with DIAGNOS compensating IBN at a rate of US$6,400 per month, payable in advance and sourced from the Corporation's cash reserves.

IBN's role will focus on amplifying DIAGNOS's visibility in the market, aimed at maximizing shareholder value and strengthening the company's profile among investors. This engagement is crucial for DIAGNOS as it seeks to reinforce its standing in the healthcare sector, where AI technology plays an increasingly pivotal role.

As an independent entity, IBN operates at arm’s length from DIAGNOS, with no current interests in the Corporation’s securities. The agreement is contingent upon approval from the TSX Venture Exchange. DIAGNOS, headquartered in Canada, is dedicated to enhancing diagnostic accuracy and improving healthcare outcomes by leveraging innovative AI solutions aimed at aiding clinicians in eye health diagnostics.

The corporation remains committed to transparent communication, with a disclaimer regarding forward-looking statements made in the announcement, emphasizing that actual results may differ from those anticipated. For more detailed insights about DIAGNOS and its operations, stakeholders are encouraged to visit the company's official websites.

For further inquiries, stakeholders can reach out to Mr. André Larente, President of DIAGNOS Inc., at the provided contact details. This strategic move positions DIAGNOS for potential growth and heightened investor interest in a rapidly evolving healthcare technology landscape.

DIAGNOS Inc. (TSX Venture: ADK, OTCQB: DGNOF) has recently announced its engagement with the Investor Brand Network (IBN) to enhance its corporate communication and market awareness strategies. This strategic move, underpinned by a monthly expenditure of $6,400 over the next year, signals DIAGNOS's commitment to improving its visibility and maximizing shareholder value through refined investor interactions.

From a market perspective, this engagement is timely as DIAGNOS operates in an innovative sector—early detection of critical health issues via Artificial Intelligence (AI). The Company’s focus on eye-related health problems positions it at the intersection of healthcare and technology, which is particularly appealing to growth-oriented investors. The increased promotion and awareness generated by IBN can potentially drive interest in DIAGNOS’s stock, especially as the healthcare technology market continues to expand.

However, investors should exercise caution. The forward-looking nature of this announcement carries inherent risks; the outcomes of such marketing efforts are not guaranteed. While the intention is to bolster shareholder value, external market conditions, competition, and the company's operational execution will ultimately shape performance.

In light of these considerations, potential investors and current shareholders should monitor DIAGNOS’s execution of its engagement with IBN closely. They should keep an eye on key performance indicators such as shareholder engagement metrics and overall trading volume in the stock post-announcement. Moreover, analyzing quarterly earnings reports will be critical to assess the tangible impact of the increased marketing spend on revenue growth and operational efficiency.

In conclusion, DIAGNOS's partnership with IBN could enhance its market profile, but investors should remain vigilant and conduct thorough due diligence in a landscape characterized by rapid technological advancements and shifting investor sentiment.